{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:44:41Z","timestamp":1787921081612,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/md.0000000000003536","type":"journal-article","created":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T20:01:53Z","timestamp":1471723313000},"page":"e3536","source":"Crossref","is-referenced-by-count":28,"title":["Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib"],"prefix":"10.1097","volume":"95","author":[{"given":"Lizhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210226","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/lary.24925","article-title":"Aggressive primary olfactory neuroblastoma of the sphenoclival region: a case report and literature review","volume":"125","author":"Purohit","year":"2015","journal-title":"Laryngoscope"},{"key":"R2-23-20210226","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1607-551X(09)70046-4","article-title":"Huge sphenoid sinus olfactory neuroblastoma: a case report","volume":"25","author":"Chan","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"key":"R3-23-20210226","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12105-009-0125-2","article-title":"Olfactory neuroblastoma","volume":"3","author":"Thompson","year":"2009","journal-title":"Head Neck Pathol"},{"key":"R4-23-20210226","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/01913129409016275","article-title":"Cushing's syndrome secondary to olfactory neuroblastoma","volume":"18","author":"Arnesen","year":"1994","journal-title":"Ultrastruct Pathol"},{"key":"R5-23-20210226","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1507\/endocrj.K07E-005","article-title":"Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review","volume":"55","author":"Koo","year":"2008","journal-title":"Endocr J"},{"key":"R6-23-20210226","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s00405-006-0048-4","article-title":"Retropharyngeal lymph node metastasis from olfactory neuroblastoma: A report of two cases","volume":"263","author":"Kim","year":"2006","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R7-23-20210226","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00405-014-3320-z","article-title":"Long-term carcinologic results of advanced esthesioneuroblastoma: a systematic review","volume":"273","author":"DeBonnecaze","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R9-23-20210226","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.anl.2007.02.005","article-title":"Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma","volume":"34","author":"Kim","year":"2007","journal-title":"Auris Nasus Larynx"},{"key":"R10-23-20210226","first-page":"399","article-title":"Targeted therapy for resistant cholangiocarcinoma with bevacizumab or cetuximab added to failed cytotoxic drug cores","volume":"36","author":"Bruckner","year":"2016","journal-title":"Anticancer Res"},{"key":"R11-23-20210226","first-page":"47","article-title":"Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations","volume":"4","author":"Milano","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"R12-23-20210226","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-015-0485-6","article-title":"Molecular targeted therapy approaches for BRAF wild-type melanoma","volume":"18","author":"Johnpulle","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"R13-23-20210226","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrd2012","article-title":"Sunitinib maleate","volume":"5","author":"Atkins","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R14-23-20210226","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-23-20210226","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R16-23-20210226","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(02)80597-4","article-title":"Regulation and targets of receptor tyrosine kinases","volume":"38","author":"Pawson","year":"2002","journal-title":"Eur J Cancer"},{"key":"R17-23-20210226","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2013focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"R18-23-20210226","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11060-009-0027-x","article-title":"Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinibmesylate","volume":"97","author":"Preusser","year":"2010","journal-title":"J Neurooncol"},{"key":"R19-23-20210226","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1158\/1078-0432.CCR-07-5165","article-title":"Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab","volume":"14","author":"Lurje","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000003536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:09:55Z","timestamp":1786039795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201605030-00023"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003536","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}